# REATA PHARMACEUTICALS INC

REATA PHARMACEUTICALS INC is a company headquartered in Plano, TX, United States.

## Company overview

- **Legal name:** REATA PHARMACEUTICALS INC
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Plano, TX, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001358762

## About

REATA PHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001358762, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-02-24, it reported annual revenue of USD 2,216,000; net income of USD -311,901,000; total assets of USD 514,491,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $2.2M (USD 2,216,000)
- **Net income:** -$311.9M (USD -311,901,000)
- **Total assets:** $514.5M (USD 514,491,000)
- **Cash and equivalents:** $42.3M (USD 42,312,000)
- **Operating cash flow:** -$204.3M (USD -204,267,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $11.5M (USD 11,490,000)
- **Net income:** -$297.4M (USD -297,386,000)
- **Total assets:** $735.0M (USD 735,016,000)
- **Cash and equivalents:** $590.3M (USD 590,258,000)
- **Operating cash flow:** -$235.7M (USD -235,701,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $9.0M (USD 9,019,000)
- **Net income:** -$247.8M (USD -247,752,000)
- **Total assets:** $857.6M (USD 857,598,000)
- **Cash and equivalents:** $818.1M (USD 818,150,000)
- **Operating cash flow:** -$322.3M (USD -322,340,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $26.5M (USD 26,517,000)
- **Net income:** -$290.2M (USD -290,170,000)
- **Total assets:** $682.4M (USD 682,420,000)
- **Cash and equivalents:** $664.3M (USD 664,324,000)
- **Operating cash flow:** -$251.2M (USD -251,151,000)

## Recent SEC filings

- Form 8-K — filed 2023-09-26 — period 2023-09-26 — 8-K
- Form 8-K — filed 2023-09-21 — period 2023-09-21 — 8-K
- Form 8-K — filed 2023-09-12 — period 2023-09-11 — 8-K
- Form 10-Q — filed 2023-08-08 — period 2023-06-30 — 10-Q
- Form SC 13D — filed 2023-08-07 — SC 13D
- Form 8-K — filed 2023-07-31 — period 2023-07-28 — 8-K
- Form 8-K — filed 2023-07-28 — period 2023-07-28 — 8-K
- Form 8-K — filed 2023-07-11 — period 2023-07-10 — 8-K
- Form SC 13G — filed 2023-06-26 — REATA PHARMACEUTICALS, INC.
- Form 8-K — filed 2023-06-20 — period 2023-06-19 — 8-K
- Form 8-K — filed 2023-06-07 — period 2023-06-07 — 8-K
- Form 10-Q — filed 2023-05-10 — period 2023-03-31 — 10-Q

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/reata-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology